Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | VDR | P11473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6216333 | 1.00 | ALDH1A1 (0.58) | ALDH1A1GLATSHRKMT2AMEN1 | |
| SCHEMBL10936580 | 0.87 | ALDH1A1 (0.55) | ALDH1A1GLATSHRHTTTDP1 | |
| SCHEMBL25279086 | 0.86 | ALDH1A1 (0.49) | ALDH1A1GLATSHRKMT2AMEN1 | |
| SCHEMBL10602219 | 0.86 | ALDH1A1 (0.59) | ALDH1A1GLATSHRNPSR1TDP1 | |
| SCHEMBL3810478 | 0.85 | ALDH1A1 (0.58) | ALDH1A1GLATSHRKMT2AMEN1 | |
| SCHEMBL8069122 | 0.85 | ALDH1A1 (0.54) | ALDH1A1GLATSHRKMT2ATDP1 | |
| SCHEMBL4218019 | 0.85 | ALDH1A1 (0.58) | ALDH1A1GLATSHRKMT2AMEN1 | |
| SCHEMBL7281360 | 0.85 | ALDH1A1 (0.61) | ALDH1A1GLATSHRMAPTHTT | |
| SCHEMBL4309017 | 0.85 | ALDH1A1 (0.51) | ALDH1A1GLATSHRKMT2AMEN1 | |
| SCHEMBL4312278 | 0.85 | ALDH1A1 (0.51) | ALDH1A1GLATSHRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-7449475-B2 | Tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| EP-1521757-B1 | TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | EP | disclosed |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | REN, TACR1, AGTR1 | ALDH1A1 1465/4885GLA 3309/4885TSHR 68/4885 |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | REN, TACR1, AGTR1 | ALDH1A1 1375/4885GLA 3218/4885TSHR 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.